» Articles » PMID: 34724150

Opioid Receptors Signaling Network

Overview
Date 2021 Nov 1
PMID 34724150
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

Opioid receptors belong to the class A G-protein-coupled receptors and are activated by alkaloid opiates such as morphine, and endogenous ligands such as endorphins and enkephalins. Opioid receptors are widely distributed in the human body and are involved in numerous physiological processes through three major classical opioid receptor subtypes; the mu, delta and kappa along with a lesser characterized subtype, opioid receptor-like (ORL1). Opioids are the most potent analgesics and have been extensively used as a therapeutic drug for the treatment of pain and related disorders. Chronic administration of clinically used opioids is associated with adverse effects such as drug tolerance, addiction and constipation. Several investigations attempted to identify the molecular signaling networks associated with endogenous as well as synthetic opiates, however, there is a paucity of a cumulative depiction of these signaling events. Here, we report a systemic collection of downstream molecules pertaining to four subtypes of opioid receptors (MOR, KOR, DOR and ORL1) in the form of a signaling pathway map. We manually curated reactions induced by the activation of opioid receptors from the literature into five categories- molecular association, activation/inhibition, catalysis, transport, and gene regulation. This led to a dataset of 180 molecules, which is collectively represented in the opioid receptor signaling network following NetPath criteria. We believe that the public availability of an opioid receptor signaling pathway map can accelerate biomedical research in this area because of its high therapeutic significance. The opioid receptors signaling pathway map is uploaded to a freely available web resource, WikiPathways enabling ease of access ( https://www.wikipathways.org/index.php/Pathway:WP5093 ).

Citing Articles

Kappa opioid receptor internalisation-induced p38 nuclear translocation suppresses glioma progression.

Li Y, Wang W, She H, Cui Z, Liu Z, Yang H Br J Anaesth. 2024; 134(3):759-771.

PMID: 39741108 PMC: 11867070. DOI: 10.1016/j.bja.2024.09.031.


Molecular Sex Differences and Clinical Gender Efficacy in Opioid Use Disorders: From Pain Management to Addiction.

Concato M, Giacomello E, Al-Habash I, Alempijevic D, Kolev Y, Buffon M Int J Mol Sci. 2024; 25(17).

PMID: 39273261 PMC: 11395529. DOI: 10.3390/ijms25179314.


Inhibition of the protective effects of preconditioning in ischemia-reperfusion injury by chronic methadone: the role of pAkt and pSTAT3.

Yeganeh-Hajahmadi M, Kordestani Z, Moosavi-Saeed Y, Rostamzadeh F Sci Rep. 2024; 14(1):14350.

PMID: 38906975 PMC: 11192952. DOI: 10.1038/s41598-024-65349-x.


miR-99b/let-7e/miR-125a cluster suppresses pancreatic cancer through regulation of NR6A1.

Li Y, Zhang G, Xu C, Shen L, Xu G, Ji K Am J Cancer Res. 2024; 14(1):114-129.

PMID: 38323281 PMC: 10839324.


Involvement of the Opioid Peptide Family in Cancer Progression.

Sanchez M, Rodriguez F, Covenas R Biomedicines. 2023; 11(7).

PMID: 37509632 PMC: 10377280. DOI: 10.3390/biomedicines11071993.


References
1.
Ziolkowska B, Urbanski M, Wawrzczak-Bargiela A, Bilecki W, Przewlocki R . Morphine activates Arc expression in the mouse striatum and in mouse neuroblastoma Neuro2A MOR1A cells expressing mu-opioid receptors. J Neurosci Res. 2005; 82(4):563-70. DOI: 10.1002/jnr.20661. View

2.
Robinson J, McDonald P . The orexin 1 receptor modulates kappa opioid receptor function via a JNK-dependent mechanism. Cell Signal. 2015; 27(7):1449-56. PMC: 5549559. DOI: 10.1016/j.cellsig.2015.03.026. View

3.
Kivell B, Uzelac Z, Sundaramurthy S, Rajamanickam J, Ewald A, Chefer V . Salvinorin A regulates dopamine transporter function via a kappa opioid receptor and ERK1/2-dependent mechanism. Neuropharmacology. 2014; 86:228-40. PMC: 4188751. DOI: 10.1016/j.neuropharm.2014.07.016. View

4.
Blake A, Bot G, Li S, Freeman J, Reisine T . Differential agonist regulation of the human kappa-opioid receptor. J Neurochem. 1997; 68(5):1846-52. DOI: 10.1046/j.1471-4159.1997.68051846.x. View

5.
Rajagopal S, Shenoy S . GPCR desensitization: Acute and prolonged phases. Cell Signal. 2017; 41:9-16. PMC: 5533627. DOI: 10.1016/j.cellsig.2017.01.024. View